Dianthus Therapeutics, Inc.DNTHNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+32.6%
5Y CAGR+84.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+32.6%/yr
vs +15.0%/yr prior
5Y CAGR
+84.1%/yr
Recent deceleration
Acceleration
+17.6pp
Accelerating
Percentile
P97
Near historical high
vs 5Y Ago
21.2x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 84.35% |
| Q3 2025 | 23.76% |
| Q2 2025 | -2.78% |
| Q1 2025 | 2.23% |
| Q4 2024 | 3.40% |
| Q3 2024 | 41.36% |
| Q2 2024 | 38.17% |
| Q1 2024 | 48.94% |
| Q4 2023 | 10.31% |
| Q3 2023 | -22.36% |
| Q2 2023 | 75.35% |
| Q1 2023 | -40.52% |
| Q4 2022 | 36.20% |
| Q3 2022 | -30.64% |
| Q2 2022 | -32.14% |
| Q1 2022 | 21.93% |
| Q4 2021 | 22.57% |
| Q3 2021 | -3.63% |
| Q2 2021 | -9.19% |
| Q1 2021 | -4.31% |
| Q4 2020 | 3.99% |
| Q3 2020 | -6.53% |
| Q2 2020 | -9.69% |
| Q1 2020 | -25.39% |
| Q4 2019 | 13.25% |
| Q3 2019 | 23.01% |
| Q2 2019 | 27.48% |
| Q1 2019 | -14.96% |
| Q4 2018 | 8.51% |
| Q3 2018 | 17.92% |
| Q2 2018 | 23.37% |
| Q1 2018 | 41.40% |
| Q4 2017 | 6.55% |
| Q3 2017 | -62.29% |
| Q2 2017 | 315.89% |
| Q1 2017 | 0.00% |